Article

HOYA clear optic IOLs gain FDA approval

HOYA Surgical Optics Inc. announced it received FDA approval for the commercial distribution of two models of clear foldable hydrophobic acrylic-optic aspheric IOLs, the iSymm (Model FC-60AD) and the preloaded iSert (Model PC-60AD), in the United States.

Chicago-HOYA Surgical Optics Inc. announced it received FDA approval for the commercial distribution of two models of clear foldable hydrophobic acrylic-optic aspheric IOLs, the iSymm (Model FC-60AD) and the preloaded iSert (Model PC-60AD), in the United States.

These lenses are an important addition to HOYA’s line of foldable and preloaded IOLs available with an optimized aspheric design, according to a prepared statement from the company.

“HOYA Surgical Optics remains strongly committed to our U.S. customers and delivering on this new direction in refractive cataract surgery,” said Jake Vander Zanden, president, Americas. “Our COMPLETE SYSTEM uses the HOYA iTrace surgical workstation with advanced wavefront diagnostics to assist surgeons in the proper selection of an IOL, based on the patient’s specific optical system.”

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.